Form 4: PLRX CHRO Lily Cheung Granted 300,000 Stock Options

Pliant Therapeutics' Chief Human Resource Officer, Lily Cheung, was granted 300,000 stock options with an exercise price of $1.30, vesting monthly over four years.

Summary

• Lily Cheung, Chief Human Resource Officer of Pliant Therapeutics, Inc. (PLRX), acquired 300,000 stock options.
• The options have an exercise price of $1.30 per share.
• The transaction date for the option grant was January 22, 2026.
• The options begin vesting on January 1, 2026, with 1/48th of the shares vesting monthly over a four-year period, contingent on continuous service.
• The expiration date for these stock options is January 22, 2036.
• Following this transaction, Lily Cheung beneficially owns 300,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine disclosure of executive compensation, which is generally viewed as a positive for aligning management incentives with shareholder interests, but it does not provide new operational or financial performance information.

Positives

• The grant of stock options aligns the Chief Human Resource Officer's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages executive retention and sustained contribution to the company's success.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an executive's equity transaction.

Industry Context

The grant of stock options to a Chief Human Resource Officer is a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and motivate senior leadership by linking their personal wealth to the company's long-term stock performance.

Comparison to Industry Standards

• The structure of this option grant, including the exercise price and a multi-year vesting schedule, is consistent with typical executive compensation practices observed across the biotechnology sector.
• Many publicly traded biotech companies, such as Gilead Sciences or Amgen, utilize similar equity-based incentives to align executive interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The option grant aligns the interests of a key executive with shareholders, potentially leading to better long-term performance.
• Employees: This reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• Lily Cheung's continued service to Pliant Therapeutics, Inc. is required for the options to vest according to the monthly schedule.

Key Dates

Keywords

Pliant Therapeutics, PLRX, Stock Options, Executive Compensation, Form 4, Lily Cheung, Insider Transaction